Fig. 3.

HBeAg status and NUC treatment impact HBV+ hepatocyte burden.

Quantification of (A) % total HBV+ hepatocytes (defined as HBsAg+ and/or HBV core+), (B) % HBsAg+ hepatocytes, and (C) % HBV core+ hepatocytes before and after NUC treatment in HBeAg+ and HBeAg- participants. (D) Representative images from HBeAg+ and HBeAg- participants throughout NUC treatment. Embedded legend indicates markers and corresponding colour. ∗p <0.05, ∗∗p <0.01, ∗∗∗p <0.001, ∗∗∗∗p <0.0001, Mann–Whitney U test. Only statistically significant differences are shown. NUC, nucleo(t)side.